Renal volume regulation is modulated by the action of cyclooxygenases (COX) and the resulting generation of prostanoids. Epithelial expression of COX isoforms in the cortex directs COX-1 to the distal convolutions and cortical collecting duct, and COX-2 to the thick ascending limb. Partly colocalized are prostaglandin E synthase (PGES), the downstream enzyme for renal prostaglandin E2 (PGE2) generation, and the EP receptors type 1 and 3. COX-1 and related components were studied in 2kidney-1clip (2K1C) Goldblatt hypertensive rats with combined chronic angiotensin (Ang) II-or bradykinin B2-receptor blockade using candesartan (cand) or the B2 antagonist, Hoechst 140 (Hoe).
Introduction
Renovascular hypertension (RVH) is a form of secondary hypertension. The two kidney-one clip rodent model of RVH (2K1C; Goldblatt model) is similar to unilateral RVH in humans. The defect is highly dependent on the enhanced activity of the renin angiotensin system (RAS). Decreased renal perfusion pressure in the compromised kidney maximally activates the RAS, and its inability to balance the rise in blood pressure is partly the result of elevated angiotensin II (Ang II) levels. The non-stenotic kidney is subject to elevated perfusion pressure, responding with "pressure natriuresis" to lower blood pressure by the excretion of sodium. In the light of systemically elevated Ang II levels and the distinct constellation of the renal perfusion pressures the RVH model is considered by some to be wholly one of increased peripheral vascular resistance, whereas others emphasize the role of volume retention (13; for review, see 14) . For the latter, elevated Ang II levels prevail in both kidneys in short term and maintenance phase affecting both, tubular transport and renal hemodynamics thereby causing long term impairments in sodium balance regulation (29, 30) .
Biological mechanisms with protective effects against hypertension and organ damage have received continuous interest and have therefore been studied also in RVH. In particular, paracrine and endocrine systems with protective potency have been analyzed for their role to oppose vascular and epithelial volume retaining effects. Among these, cyclooxygenases (COX) and the prostaglandin system have received particular interest during the past decade for their involvement in the regulation of vascular tone and renal excretory function (for review, 9).
Apart from their vascular (20) and renal medullary interstitial action (42) , renal prostaglandins have a tubular epithelial-bound focus in the cortical distal nephron and collecting duct system. Here, COX and downstream prostaglandin E synthase (PGES) show distinct cellular distribution, and prostaglandin E2 (PGE2) , the major prostaglandin produced along the nephron, may bind to colocalized EP1 and EP3 prostaglandin receptors to exert potent diuretic and natriuretic effects (2, 4, 5, 35) . Since prostanoids are rapidly degraded, their action in the intimate vicinity of where they are produced, must be assumed.
Expression of COX-2 within the thick ascending limb (TAL) is regulated by Ang II and probably modulates renal renin production (31, 37, 41) and may promote afferent vasodilation (19) , although its role in juxtaglomerular signalling in RVH has been questioned (16) . Less attention has been paid to COX1 expression in RVH. COX-1, co-expressed with PGES, provides avid prostaglandin synthesis in the terminal distal convoluted tubule (DCT), connecting tubule (CNT), and cortical collecting duct (CCD) (5, 35) . The EP1 and EP3 prostaglandin receptors have been co-localized to these segments as well, probably mediating reduced NaCl and water absorption, promoting natriuresis and diuresis (4), although acute inhibition experiments have questioned this role for COX-1 (34); a functional concept with the activities of COX-1 and COX-2 acting antagonistically has thus been stated. In contrast to COX-2, cortical COX-1 has widely been considered as a constitutive enzyme with little or no adaptive response to variations in hemodynamics and renal urine concentrating functions (23, 26, 42) . Together, the available evidence thus far has not reached consense on the particular role of cortical COX-1 and the co-localized related components.
Given that the abundant expression of these components in the late distal epithelia would adapt to functional stimuli, this may demonstrate their functional significance. To test this, we have chosen the 2K1C model during early maintenance phase for its extremely divergent renal functional adaptations within one organism, prior to the rise of parenchymal alterations. Cortical expression of COX-1, PGES, and EP-1 and EP-3 receptors was assessed to consider their potential role in natriuresis and diuresis. The status of the cortical L-arginine-NO system was studied in parallel, since interference and synergistic effects with COX can be assumed (10, 24, 40) . The possible interaction of Ang II with these parameters in 2K1C was monitored using candesartan. To test whether the topographically colocalized renal tissue kallikrein kinin system (KKS; 12) interacts, these parameters were further assessed under B2 receptor blockade. The renal KKS interferes with the RAS on the vascular side, but is also likely to affect bradykinin B2 receptor-mediated tubular effects on diuresis and natriuresis, in part by stimulating PGE2 release (11, 17, 25) . Our results have revealed reduced expression of cortical COX-1 and functionally related parameters in early RVH, with minor changes upon RAS or KKS inhibition. We conclude that reduced cortical epithelial COX-1 metabolites could be related to impaired volume handling in RVH.
Materials and Methods
Animal preparation. Young male Sprague-Dawley rats weighing 140±7 g were obtained in part from the local animal facility of the Charité hospital, Berlin, and in part from Iffa Credo, Paris. All animals had free access to standard chow and tap water. A total of 60 rats were subdivided into 6 groups by random selection (each n=10, half and half divided for morphological and biochemical evaluation, treatment was designed to study the initial phase since after 4 d the renin angiotensin system is expected to be maximally stimulated, yet without concomitant secondary tissue damage. For surgery, animals were anesthetized with pentobarbital sodium (50 mg/kg i.p.), then the left renal artery was isolated via laparotomy; a 0.2-mm silver clip was placed around the left renal artery in the animal designated for clipping (4) . In sham operated animals the left renal artery was exposed and surrounding fat and connective tissue was gently removed. Blood pressure was measured by tail-cuff plethysmography in conscious rats on the last three days of the experiment. On the last day rats were placed in metabolic cages during 24 h for urine collection. For immunohistochemical analysis rats were anesthetized and perfused retrogradely through the abdominal aorta using 330 mosmol sucrose/PBS (pH 7.4) during 20 s for blood rinsing, followed by 3% paraformaldehyde/PBS for 5 min. Laboratory parameters. Urinary sodium and potassium concentrations were determined by flame photometry (FLM3, Radiometer) or by ion-selective electrode (Konelab microlyt 3+2). Urinary creatinine levels were determined in 10µl probes by an Ortho Diagnostics system and read by a Kodak Biolyser. Urinary kallikrein was measured colorimetrically (405 nm) using glandular kallikrein as a standard (S2266 Chromogenix Instrumentation, Coger). Urinary prostanoids were measured by gas chromatography and tandem mass spectrometry; prostaglandin E 2 (PGE 2 ), 6-keto-prostaglandin F 1α  (6kPGF 1α ), and thromboxane B 2 (TXB 2 ) were determined as described (38) .
Immunohistochemistry. Cryostat or paraffin sections (5 µm) were used. Paraffin sections were dewaxed, rehydrated, immersed in citrate buffer (pH 6.0), heated in a microwave oven for 20 min, incubated with 5% skim milk in PBS (pH 7.4) containing 0.5% Triton X-100 overnight, followed by primary antibody for 2 h at room temperature and then overnight at 4°C. Signal was generated using an amplification kit containing biotinylated IgG and streptavidin-peroxidase (DAKO, Hamburg, Western blot analysis. For membrane fractionation kidney cortex was minced and homogenized in 10 ml dissecting buffer containing 0.3 M sucrose, 25 mM imidazole, 1 mM EDTA and proteinase inhibitor cocktail, pH 7.2. Homogenates were centrifuged for 15 min at 4,000 xg (4°C). The pellet was rehomogenized to increase yields. Supernatants were pooled and centrifuged at 17,000 xg for 30 min to obtain a fraction enriched for plasma membranes and part of the microsomal fraction. The pellet was resuspended in PBS containing 2.5% Triton X-100. Protein concentration was assayed for rough estimation by spectrophotometric analysis at 280 nm, and Bradford's assay using BCA kit (Pierce) was performed throughout for definitive measurements. Equal loading was controlled by Coomassie staining of the SDS-PAGE gels, and Ponceau staining was applied on membranes after blotting.
Protein fractions were solubilized in Laemmli's buffer, incubated for 10 min at 85°C and separated in 10-12% SDS-PAGE. Proteins were transferred onto PVDF membranes (BioRad, Richmond, USA).
Membranes were incubated overnight at 4°C with 10% skim milk/PBS containig 0.1 mM levamisole for 1 h at 37°C and probed with anti-COX-1 (dilution 1:500), anti-mPGES (1:500), anti-EP1 (1:2,000), anti-EP3 (dilution 1:1000), or monoclonal mouse anti-ß-actin (1:20,000; Sigma) used for normalizing data with housekeeping ß-actin expression. After washing in 0.5% Tween/PBS membranes were incubated with alkaline phosphatase-conjugated secondary antibody (Promega, Heidelberg, Germany) followed by signal revelation using nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate complex. Membranes were evaluated by measuring density of pixels/area using PDQuest 2-D image analysis system (BioRad).
RT-PCR analysis. Total RNA from kidney cortex was extracted using the guanidinium thiocyanate method. All samples were quantified by spectrophotometric analysis at 260 nm. Five micrograms of total RNA were reverse transcribed. The following sets of oligonucleotide primers were used to amplify cDNA: 5´-TATCCGTTGTGGATCTGAC-3´and 5´-TGGTCCAGGGGTTTCTTAC-3´(GAPDH; 300 bp); and ´5´-CCTTCCGTGTGCCAGATTA-3´and 5´-GGCTGGCCTAGAACTCATCC-3´(COX-1; 475 bp) and 5´-ACACTCTATCACTGGCATCC-3´and 5´-GAGGGACACCCTTTCACAT-3´(COX-2; 585 bp). Amplification was performed using Taq polymerase for 30-35 cycles with an automated thermal cycler (Perkin Elmer, Weiterstadt, Germany). Each cycle consisted of the following steps: denaturation at 98°C, annealing at 63°C, and extension at 72°C. Semiquantitative PCR was performed using specific primers for COX-1 or COX-2, as well primers for GAPDH in the respective tube as described (1) . PCR-products were separated in 1% agarose gels and stained with ethidium bromide. The amplified fragments had the expected length and were validated by DNA sequencing.
Measurements of renal cortical cGMP levels. Renal cortices (n=5 per group) were isolated, frozen, homogenized, and assayed using an enzyme-linked immunosorbent assay as described (39) .
Presentation of data and statistical analysis. Quantitative data are presented as means ±SD or ±SEM, as indicated in the legends. For statistical comparison, the unpaired t-test (when variances were the same) or the Mann-Whitney rank sum test (when variances differed significantly between groups) was employed. P values of less than 0.05 were considered statistically significant.
Results
Physiological parameters. Blood pressure was significantly increased in the 2K1C group, equally high in the 2K1C+Hoe group, and near normal in the 2K1C+cand group (Table 1A) . Urine flow was significantly increased in all 2K1C groups, whereas no significant changes in fractional sodium excretion levels were registered. Kallikrein excretion was diminished in 2K1C and 2K1C + cand groups, but unchanged in the 2K1C+Hoe group; referring the latter to the sham+Hoe group, however, a diminution was evident as well (p<0.05). Cand and Hoe treatments in the sham groups caused no significant changes.
COX-1.
Immunoreactive COX-1 was localized to the extraglomerular mesangium and DCT, CNT and CCD with exception of the intercalated cells. Changes in signal intensity among the different conditions could be qualified and have been documented exemplarily (Fig. 1A to C) . Densitometric evaluation of Western blot analysis revealed a decrease in both kidneys of all 2K1C groups as compared to the untreated sham group except for the contralateral 2K1C+cand condition (clip vs. nonclip kidneys, changes ±SEM: 2K1C, -53±3 vs. -34±5%; 2K1C+cand, -79±4% vs. no change; 2K1C+Hoe, -48±4 vs. -32±4%) whereas the kidneys of the sham groups receiving cand or Hoe were unchanged (Fig. 2) ; values have been normalized for ß-actin. Results were verified at the mRNA level using semiquantitative RT-PCR from extracts of the kidneys of sham and 2K1C groups; changes were similar to the Western blot data (not shown).
COX-2.
Immunoreactive COX-2 was localized in macula densa area and in scattered TAL cells.
Numerical evaluation of these immunoreactive cells revealed the following changes in COX-2 signal in the 2K1C groups as compared to the untreated sham group (clip vs. nonclip kidneys): 2K1C, +107±3 vs. -68±3%; 2K1C + cand, 494±51 vs. +344±15%; 2K1C + Hoe, +49±9 vs. -51±2% (Fig. 2) .
The kidneys of the sham+cand group showed a +420±32% change, the sham+Hoe group -26±3%.
Results were verified at the mRNA level using semiquantitative RT-PCR from extracts of the kidneys of the sham and 2K1C groups; changes were similar to the immunohistochemistry data (not shown).
PGES.
Immunoreactive PGES was localized to the macula densa, DCT, CNT and CCD with exception of the intercalated cells. Changes in signal intensity in the experimental conditions have been documented exemplarily (Fig. 1D to F) . Western blot analysis revealed a decrease in both kidneys of all 2K1C groups as compared to the untreated sham group (clip vs. nonclip kidneys):
2K1C, -54±2 vs. -31±3%; 2K1C+cand, -93±3% vs. no change; 2K1C+Hoe, -58±5% vs. no change).
The kidneys of the sham+cand group were unchanged, and of the sham+Hoe group reduced (Fig.   1,2) .
EP1. The EP-1 receptor was localized to the macula densa and neighboring TAL profiles, to CNT and CCD principal cells; signal was luminally enhanced (Fig. 1G to i) . Western blot analysis revealed a decrease of EP-1 abundance in the clip kidneys of all 2K1C groups as compared to the untreated sham group: 2K1C, -65±4% vs. no change; 2K1C+cand, -93±2% vs. no change; 2K1C+Hoe, no changes. The nonclip kidneys were not different from the controls. The pooled kidneys (right and left kidney) of the sham groups receiving cand or Hoe were unchanged throughout (Fig. 2) . Fig. 1K to M) . Western blot analysis revealed changes in EP-3 abundance in the 2K1C groups compared to the untreated sham group as follows (clip vs. nonclip kidneys): 2K1C, no change vs. +156±16%; 2K1C + cand, -55±3 vs. +200±16%; 2K1C + Hoe, no change vs. +109±13%. The kidneys of the sham groups receiving cand or Hoe were increased by 172±25S and 100±2%, respectively (Fig. 2) .
EP3. Immunohistochemistry localized EP-3 immunoreactivity mainly in TAL (

Urinary prostaglandin excretion. Prostaglandin E 2 excretion was significantly reduced in the 2K1C
group (-65±3%) and the 2K1C+Hoe group (-61±2%) as compared to the untreated sham group, whereas the other groups showed no differences (Table 1B) . Urinary excretion of thromboxane B 2 and prostaglandin F 1α revealed no changes either (Table 1B) .
Cortical NO parameters -NOS1. Juxtaglomerular NOS1 expression as the major source of cortical constitutive NO production was quantified. Numerical evaluation of the immunoreactive cells revealed the following changes in NOS1 signal in the 2K1C groups as compared to the untreated sham group (clip vs. nonclip kidneys): 2K1C, +40±1 vs. -22±6%; 2K1C + cand, 129±19 vs. +69±14%; 2K1C + Hoe, +4±14 vs. -32±9%. The kidneys of the sham+cand group showed a +99±15% change, the sham + Hoe group -26±3% (Fig. 2) .
Cortical NO parameters -cGMP. Cortical cGMP levels in the 2K1C groups as compared to the untreated sham group (clip vs. nonclip kidneys) were as follows: 2K1C, -10±4 vs. -36±3%; 2K1C + cand, -33±7 vs. -53±4%; 2K1C + Hoe, -50±5 vs. -53±8%. The kidneys of the sham + cand group showed a -15±5% change, the sham + Hoe group -27±13% (Fig. 2) .
A summary of the changes in the experimental groups is presented in Table 2 . Tendencies for coordinate changes of the cortical products, grouped together according to their common localization or biochemical relation, have been indicated in the 2K1C groups by color labels to facilitate an overview of the major results.
Discussion
The rational of the present experiments was to characterize changes of the components of the renal cortical prostaglandin system and of potentially interfering products of the cortical L-arginin-NO system in RVH. The model was chosen for its highly divergent hemodynamic and regulatory configuration of the stenotic vs. contralateral kidneys. The potential influences of chronic inhibition of the RAS, which should improve the condition, and of the KKS, which should aggravate the condition, were assessed. In our setting of an initial, short term maintenance phase the clipped kidney is expected to have an established low RPF, reduced GFR, stimulated macula densa response, and elevated juxtaglomerular parameters; the inverse constellation would characterize the contralateral kidney. Major parenchymal changes are not to be expected within the selected time span (3). Plasma RAS levels are typically high under this condition and renal Ang II levels are elevated in both kidneys, whereas renin levels are high in the clip kidney and reduced in the nonclip side (29, 30) . By contrast, kallikrein activity is reduced principally in the clip kidney, and normal or decreased in the nonclip kidney (25) . Changes of COX and related parameters, which we have registered in the present experiments, were analyzed to permit new insights into their potential roles in the development of RVH.
Our results have in part corroborated, and in part extended available data on changes in inducible COX-2 of TAL and macula densa region as the major source of cortical PGE2 synthesis (33, 40, 41) .
Chronic blockade of the Ang II AT1 receptor had a marked additive effect resulting in a four-fold increase of COX-2 over control level on the stenotic side, similar to previous data on the coordinate changes of COX-2 and renin (18) . It further led to an equally drastic rise in COX-2 signal in the contralateral kidney. COX-2 metabolite-dependent modulation of macula densa-mediated renin synthesis and release has been established, involving PGI2-or PGE2 mediated activation of local EP2 and EP4 receptors, and a causal relation between these products is likely to play a role in RVH (20, 32, 36, 37) . Chronic Hoe treatment prevented the induction of COX-2 expression in the stenotic kidney, but had inconspicous effects in the control and clip conditions. RVH was earlier shown to present with increased B2 receptor density in both kidneys (11) , which may be explanatory to the fact that abrogation of kinin function has been worsening the development of RVH, possibly via reduced prostaglandin formation and consequent reduction in renal blood flow and sodium excretory ability (25) . The full expression of COX-2 further appears to require intact B2 receptor function (21) .
Alternatively, however, Hoe-induced reduction of NOS1 expression in RVH may have interfered with COX-2 (7), possibly through a p38 MAPK-dependent pathway as recently proposed (10) . The conspicous changes of NOS1 and COX-2 in the 2K1C groups with and without Hoe may support this view.
The major new finding of the present study, however, was that cortical COX-1 expression showed major changes as well in the present experimental conditions. Previous functional studies have highlighted substantial activity of COX-1 in the cortical vasculature, probably determining Ang IIstimulated increases in prostaglandins of the renal venous blood via calcium-liberating effects (for review, 36 ). Yet, in our hands cellular localization has indicated a clear prevalence of COX-1 in the terminal nephron and collecting duct system (5); it is further plausible that these sites in addition to the medullary sources of COX are suitably localized to determine urinary prostaglandin excretion (2).
Unlike COX-2, COX-1 was downregulated in both, the clip and the nonclip kidneys in RVH. Changes in PGES expression were parallel to COX-1, and these parameters were further coordinate with an approximately 65% decrease in PGE2 urinary output. Currently available data provides no specific mechanisms for these changes, and most data on COX-1 have come from studies in the renal inner medulla where tonicity appears to play a role in its regulation (6, 23 ). Yet, the present conditions cannot easily be related with cortical cell volume or transport status. In this regard, rats with central diabetes insipidus were compared to AVP-supplemented rats, showing no change in cortical COX-1 expression (23). Another COX-2 induced mechanism, involving transport-dependent activation of the p38 MAP kinase pathway in TAL and macula densa epithelium (8) , to date has not been identified for COX-1 in the late distal tubule or collecting duct, and an attenuation of COX-1 expression by Ang II via the AT1 receptor, as shown for COX-2 (18), is not entirely evident from the present data either. In controls, cand only numerically but not significantly increased COX-1, which is in contrast to the drastic increases in the juxtaglomerular parameters under this condition. In the clip + cand kidneys, COX-1 was even further reduced by the Ang II blocker, whereas in the nonclip + cand kidney, the decrease observed in the untreated clip groups was blunted. Although the latter result would parallel changes seen with COX-2, the present data are not sufficiently clearcut to conclude that cortical COX-1 were under the same negative feedback control, as defined earlier for cortical COX-2.
Regarding the measured changes in PGES expression, available information on the physiological regulation of this terminal enzyme for PGE2 biosynthesis (35) is scarce as well, with most data coming from an inflammatory background (22) . The coordinate changes of COX-1 and PGES in the 2K1C as well as 2K1C + cand groups are obvious from the present results, but it remains to be discovered whether changes of COX-1 and PGES are coupled by common mechanisms. The changes of PGES under cand mirror those of COX-1, with an equally ambigous indication for an influence by Ang II.
Since COX-1/PGE2 signalling in the distal epithelia occurs mostly through the activation of EP1 and EP3 receptors (15, 27, 35) , we have quantified their expression as well. However, uniform changes in the two products were not detected, and only in the clip and the clip + cand kidneys a downregulation of EP1 was paralleled by COX-1. EP3 expression showed no clear correlations, possibly since in our hands its localization was more focussed to the TAL than to late distal segments, and in TAL, coupling to COX-isoforms would be less evident from the available data. The observed, focal occurrence of coordinate changes of receptor and COX products thus has no clear implications on the mode of prostaglandin signalling in our experimental setting.
Comparing our data on COX-1 and PGES with the parameters of the L-arginine-NO system we have considered that NO of juxtaglomerular origin may potentially reach downstream nephron segments to possibly affect the expression of these products. Of note, other sources of NO, which have not been considered here, may be involved. In the clip kidneys of 2K1C, there was no clear correlation between NO status and COX-1. In the nonclip kidneys, however, changes in COX-1 and PGES paralleled those of juxtaglomerular NOS1 and cortical cGMP levels. Reductions in NOS1 levels in nonclip kidneys of the 2K1C and also 2K1C + Hoe groups suggest functional relations with COX-1 as outlined above for juxtaglomerular COX-2. Likewise, cGMP in these kidneys was lowered. This may suggest a potentially synergistic effect on distal volume handling by the two systems in the context of pressure natriuresis of the contralateral Goldblatt kidney (24) .
Focussing on the tissue KKS and on kinins as potent enhancers of renal prostaglandin synthesis with particular respect to distal tubule and collecting duct function, we found marked attenuations in kallikrein excretion in RVH except for the Hoe treated 2K1C group. The findings agree with published data on diminished KKS activity, contributing to the pathogenesis of RVH by the failure to oppose vasoconstriction and concomitant diminution in fluid and electrolyte transport (17) . Ang II blockade failed to alter the reduction in kallikrein, and an interdependence of local renal kallikrein synthesis and angiotensin signalling is not obvious (for review, 28). Treatment with Hoe normalized urinary kallikrein excretion when compared to untreated sham values; intra-group comparison, however, revealed similar, significant reduction of this enzyme as in the other groups. Also the cortical quantity of COX-1 and the urinary PGE2 levels were largely unaffected by the B2 receptor blockade. In parallel we have further analyzed B2 receptor deficient mice and controls under steady state conditions, but failed to detect any changes with respect to COX-1 and -2, PGES, EP1 or EP3 protein abundance between strains either (results not shown); the localization of these products in mouse in our hands was not principally different from that in rat kidney. The absence of cortical COX-1 changes in the knockouts agrees with previous data from whole kidney extracts (21) , so that the evidence is against specific interactions between the KKS and COX-1 or its metabolites in the late distal and collecting duct epithelia in early RVH. In fact, most of the available data has ascribed to the B2 receptor function in early RVH an antihypertensive, protective role preferentially acting on the vascular side, buffering Ang II vasoconstrictor effects (7, 25) . Table 1 Clinical parameters, renal function. Parameters were measured on day 4 of the study. A, BP, blood pressure; U V , urinary volume excretion; U Na , urinary sodium excretion; FE Na , fractional sodium excretion; U K , urinary potassium excretion; U kallikrein , urinary kallikrein excretion. B, urinary excretion of prostaglandins (PG). Means ± SEM; all changes refer to untreated sham controls; * P < 0.05; n = 5 for each group. Table 2 Summary of changes in renal cortical protein abundance, cortical tissue cGMP levels, and urinary prostaglandin production. COX, cyclooxygenase; PGES, prostaglandin E synthase; EP, prostaglandin E receptor; NOS, nitric oxide synthase; cGMP, cyclic guanosine monophosphate; U PGE2 ; urinary prostaglandin E 2 excretion. All changes refer to untreated sham controls and are indicated as ↑, significant increase; ↓, significant decrease; →, no significant change. Tendencies for coordinate changes of the cortical products, hypothetically grouped together including "no change" parameters, are indicated in the 2K1C groups by blue vs. green labels. Note that contrary to the cortical parameters, U PGE2 may not only reflect cortical but also medullary prostaglandin output. Table 1   A   sham  2K1C  sham+cand  2K1C+cand  sham+Hoe  2K1C+Hoe Table 2 COX-1
